检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:石汉平[1] 齐德林[1] 黄祥成[1] 徐洁[2] 杨瑞和[2]
机构地区:[1]广州第一军医大学南方医院普外科,广州510515 [2]上海长海医院急诊科,上海200433
出 处:《中国危重病急救医学》1998年第3期167-169,共3页Chinese Critical Care Medicine
基 金:全军九五指令性攻关课题
摘 要:目的;观察低血容量性休克早期患者血浆IL-1活性的变化及其与β-内啡肽(β-EP)、内毒素的关系。方法:患者从受伤至入院后平均50分钟采血样,血浆IL-1、β-EP和内毒素分别采用改良LAF法、放射免疫法和显色基质偶氮法测定。结果:休克患者血浆IL-1活性显著高于对照组,其中死亡患者又显著高于存活患者;休克患者血浆β-EP含量与对照组比较有显著增加,且与IL一1活性密切相关,但存活与死亡患者之间无明显差异;存活患者血中内毒素水平无明显变化,而死亡患者则显著升高,与IL-1活性也呈显著正相关。结论:低血容量性休克患者早期血浆IL-1活性升高,其机制可能与β-EP升高有关;死亡患者外周血内毒素水平上升,可能是造成其血浆IL-1活性更为增加的重要原因。Objective: To observe the change in plasma interleukin - 1 (IL -l) activity and its relation to β - endorphine (β - EP) content and endotoxin level in patients with hypovolemic shock. Methods:Blood samples were collected in trauma patients about 50 minutes after injuries. Plasma IL - 1,β- EP and endotoxin were assayed by LAF, radioimmunoassay and limulus test, respectively. Results: Asignificant elevation in plasma IL - 1 activity was observed in patients with hemorrhage compared withnormal controls,and IL - 1 activity was much higher in dead cases than in survivors. Meanwhile,plasmaβ - EP was markedly increased in patients after hypovolemic shock,and it was closely related to IL - 1activity. No significant difference in plasma β- EP was found between survivors and non - survivors (P>0. 05). In addition,there was no marked increase in plasma endotoxin level in survivors,but it was significantly elevated in non -- survivors and positively correlated with plasma IL - 1 activity. Conclusions:Plasma IL - 1 activity appears to be remarkably increased at the early stage of hypovolemic shock,whichis associated with β - EP formation. Elevation of circulating endotoxin levels may be an important factorcontributing to marked release of IL - 1 in patients with fatal outcome.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28